Business Description
Mendus AB
SIC : 2834
ISIN : SE0022239950
Compare
Compare
Traded in other countries / regions
IMMU.Sweden1YG0.GermanyIMMUs.UK IPO Date
2019-09-30Description
Mendus AB is a clinical-level biopharmaceutical company based on the company's allogeneic dendritic cell biology focused on the development of immunotherapies that address tumor recurrence and hard-to-treat established tumors. Its operations consist of research and development for pharmaceuticals.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 3.64 | |||||
Equity-to-Asset | 0.94 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.24 | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 41.9 | |||||
3-Year EPS without NRI Growth Rate | 41.1 | |||||
3-Year FCF Growth Rate | 19.8 | |||||
3-Year Book Growth Rate | -39.4 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 62.58 | |||||
9-Day RSI | 68.24 | |||||
14-Day RSI | 66.75 | |||||
6-1 Month Momentum % | -43.38 | |||||
12-1 Month Momentum % | -31.85 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 7.24 | |||||
Quick Ratio | 7.24 | |||||
Cash Ratio | 4.32 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -68.5 | |||||
Shareholder Yield % | -64.59 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -17.26 | |||||
ROA % | -15.32 | |||||
ROIC % | -20.7 | |||||
ROC (Joel Greenblatt) % | -231.68 | |||||
ROCE % | -16.05 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.61 | |||||
Price-to-Tangible-Book | 2.95 | |||||
EV-to-EBIT | -3.8 | |||||
EV-to-EBITDA | -3.98 | |||||
EV-to-Forward-EBITDA | -3.48 | |||||
EV-to-Forward-Revenue | 134.69 | |||||
EV-to-FCF | -2.99 | |||||
Price-to-Net-Current-Asset-Value | 3.79 | |||||
Price-to-Net-Cash | 8.84 | |||||
Earnings Yield (Greenblatt) % | -26.32 | |||||
FCF Yield % | -30.03 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mendus AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -0.273 | ||
Beta | 1.24 | ||
Volatility % | 333.57 | ||
14-Day RSI | 66.75 | ||
14-Day ATR (€) | 0.057061 | ||
20-Day SMA (€) | 0.661425 | ||
12-1 Month Momentum % | -31.85 | ||
52-Week Range (€) | 0.084 - 1.158 | ||
Shares Outstanding (Mil) | 50.36 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Mendus AB Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Mendus AB Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Mendus AB Frequently Asked Questions
What is Mendus AB(STU:1YG0)'s stock price today?
The current price of STU:1YG0 is €0.80. The 52 week high of STU:1YG0 is €1.16 and 52 week low is €0.08.
When is next earnings date of Mendus AB(STU:1YG0)?
The next earnings date of Mendus AB(STU:1YG0) is 2024-08-23.
Does Mendus AB(STU:1YG0) pay dividends? If so, how much?
Mendus AB(STU:1YG0) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |